| Literature DB >> 33394094 |
Kirti Kajal1, Sayantan Bose1, Abir K Panda1, Dwaipayan Chakraborty1, Sreeparna Chakraborty1, Subhadip Pati1, Tania Sarkar1, Subhanki Dhar1, Dia Roy1, Shilpi Saha1, Gaurisankar Sa2.
Abstract
The initiation of new blood vessel formation (neo-angiogenesis) is one of the primary requirements for the establishment of tumor. As the tumor grows beyond a certain size, a hypoxic-condition arises in the inner core of tumor, triggering the release of chemokines, which attract T-regulatory (Treg) cells in the tumor-site. The presence of FOXP3, a lineage-specific transcription factor, expressing Treg cells in various types of tumor implements immunosuppressive and tumor-promoting strategies. One such strategy is the invitation of endothelial cells for neo-vascularization in the tumor site. Here we report that as the disease progresses, Treg cells from breast cancer patients are capable of secreting high-amount of VEGFA. The VEGFA promoter lacks Treg-specific transcription factor FOXP3 binding site. FOXP3 in association with locus-specific transcription factor STAT3 binds to VEGFA promoter to induce its transcription in Treg cells obtained from breast cancer patients. Treg cell-secreted VEGFA induces neo-angiogenesis from endothelial cells under in-vitro conditions. Targeting Tregs in mice with breast tumor reduces tumor growth as well as the level of neo-angiogenesis in the tumor tissue.Entities:
Keywords: Endothelial cell; FOXP3; Neo-angiogenesis; STAT3; Treg cells; VEGFA
Year: 2021 PMID: 33394094 DOI: 10.1007/s00262-020-02808-0
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.968